Answers are grounded in this paper and cite their sources.
The studies were conducted to substantiate the safety and immunoregulatory efficacy of Immunocol-vet through a quantitative assessment of the dynamics of proinflammatory and anti-inflammatory cytokines and complement components, confirming the absence of hyperinflammatory potential while maintaining the functional activity of the immune response. The experiments were performed in 2025-2026 on 5 groups (15 animals each) of Wistar albino rats (weight 200 ± 10 g). The experimental design included studying the following options: intact control, pyrogenal, polyacrylic acid (PAC), Escherichia coli anatoxin, Immunocol-vet (a combination of pyrogenal, PAC, and anatoxin). The drugs were administered intramuscularly at 0.2 ml three times (days 1, 3, and 7). Blood was collected on days 3, 7 and 10 (before the next administration) with subsequent enzyme immunoassay of immunological markers (cytokines IL-2, IL-4, IL-6, IL-10, IL-1β, TNF-α and complement components C3, C5). On day 3, Immunocol-vet maintained IL-4 at the control level (16.71 vs. 18.18 pg/ml), pyrogenal reduced it to 1.5 pg/ml with an increase in IL-10 to 27.4 pg/ml. By day 7, pyrogenal induced a peak of IL-6 (14.35 pg/ml) and a decrease in IL-4 to 0.17 pg/ml and C5 to 0.27 ng/ml. In the presence of Immunocol-vet, on the 7 th day, IL-6 remained minimal (0.05 pg/ml), IL-4 remained at a functional level (4.37 pg/ml), and IL-1β was effectively suppressed (0.83 pg/ml). On the 10 th day, Immunocol-vet restored IL-4 to control values (9.66 pg/ml versus the control of 9.47 pg/ml) and increased IL-2 to 13.42 pg/ml. The TNF-α indicator in the group receiving Immunocol-vet by the 10th day was 120.18 pg/ml and was lower than the control (145.61 pg/ml), while in the group receiving pyrogenal, its value reached a maximum for the entire experiment (196.55 pg/ml). Immunocol-vet exhibits immunoregulatory properties: the combination of components (pyrogenal, PAK, and toxoid) ensures an early immune response followed by physiological inhibition of the inflammatory cascade, preservation of the Th2 component (IL-4), and control of pyrogenic IL-1β without the risk of developing hyperinflammation or early immunosuppression.
No takes yet. Share an insight, caveat, or question.
Tishchenko et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: